Biovex Phase III trial meets primary endpoint

Biovex’s acquirer Amgen announces Phase III trial of talimogene laherparepvec in melanoma has met its primary endpoint.

16% of treated patients achieved a durable response as compared to 2% of control patients. This difference was statistically significant.

BioVex Limited

BioVex Limited
Oncology drug development

Website
www.amgen.com

Downloads

DownloadPress Release

Latest News

HLS Therapeutics announces Health Canada grants medical device license for CSAN PRONTO

HLS Therapeutics Inc. announces that Health Canada has granted a medical device license for the Athelas One WBC System, marketed as CSAN PRONTO, for use as a point-of-care device indicated for quantitative determination of white blood cells and neutrophil percentages in capillary or venous whole blood.

Valneva Completes Recruitment for Phase 2 Studies of its Lyme Disease Vaccine Candidate VLA15

Valneva has announced that it has completed patient recruitment of the Phase 2 studies for its Lyme disease vaccine candidate, VLA15.

Baxter Announces Acquisition of Cheetah Medical

Baxter International Inc., a leading global medical products company, today entered into a definitive agreement to acquire Cheetah Medical, a leading provider of non-invasive hemodynamic monitoring technologies

Zipline announces positive results from two significant clinical studies

ZipLine Medical, Inc. has announced publication of positive results from two significant clinical studies in two peer- reviewed journals demonstrating that use of Zip® Surgical Skin Closure leads to better clinical outcomes and healthcare cost savings than do surgical staples

Valneva reports strong operational performance and major corporate progress with H1 2019 results

Valneva has reported that its H1 2019 results are marked by strong operational performance and major corporate progress; regaining control of key R&D assets and strengthening its financial outlook with $23 million CEPI chikungunya grant

Valneva initiates second Phase II study for its Lyme Disease vaccine candidate

Valneva has announced the initiation of the second study of Phase 2 clinical development for its leading, unique Lyme disease vaccine candidate VLA15